BRAF and cancer: The limited duration of the immune response conceivably contributes to the lack of long-term benefits of BRAF/MEK inhibitor treatment in the majority patients, as increasing evidence has shown that therapeutic drugs that lead to effective anti-cancer immune responses can achieve long-lasting tumour regression [28, 29].